Semaglutide (Wegovy and Ozempic) is an FDA-approved GLP-1 agonist for type 2 diabetes and weight management, which works by suppressing appetite, slowing gastric emptying, increasing feelings of fullness, and reducing calorie intake
Udder cleft dermatitis (UCD), a multifactorial dermatological condition of the udder skin, is characterized by overgrowth of opportunistic bacteria and impaired skin barrier function
Whether this reflects actual quality differences or placebo effect is impossible to determine from anecdotal reports, but the consistency of this feedback across multiple reviewers is notable
We previously demonstrated that these doses and durations of treatment do not alter cortical neuron viability or increase oxidative stress (16)
10.1258/acb.2007.007068 136
This reduction correlated with impaired motor function and the development of compulsive drug-seeking behaviors (Sekine et al., 2001)